Top Page
Intelligent Bio Solutions
(NASDAQ:INBS)
Intelligent Bio Solutions (INBS) vs. SPDR S&P 500 ETF (SPY)
Intelligent Bio Solutions Business Overview & Revenue Model
Intelligent Bio Solutions Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.29M | 3.05M | 3.11M | 1.26M | 0.00 | 1.98M |
| Gross Profit | 1.42M | 1.25M | 1.43M | 326.67K | 0.00 | 1.98M |
| EBITDA | -9.64M | -9.45M | -9.31M | -9.47M | -8.33M | 0.00 |
| Net Income | -10.87M | -10.57M | -10.16M | -10.63M | -8.31M | -7.04M |
Balance Sheet | ||||||
| Total Assets | 10.04M | 8.25M | 13.78M | 10.35M | 12.35M | 21.86M |
| Cash, Cash Equivalents and Short-Term Investments | 1.66M | 1.02M | 6.30M | 1.54M | 8.28M | 12.57M |
| Total Debt | 1.95M | 281.81K | 1.15M | 1.92M | 0.00 | 0.00 |
| Total Liabilities | 6.61M | 5.44M | 5.60M | 6.67M | 5.81M | 6.85M |
| Stockholders Equity | 3.62M | 3.00M | 8.33M | 3.80M | 6.62M | 15.06M |
Cash Flow | ||||||
| Free Cash Flow | -10.44M | -9.91M | -9.79M | -7.88M | -3.74M | -11.30M |
| Operating Cash Flow | -10.14M | -9.68M | -9.57M | -7.38M | -3.36M | -11.30M |
| Investing Cash Flow | -302.24K | -231.84K | -221.43K | -694.14K | -880.22K | 0.00 |
| Financing Cash Flow | 8.11M | 4.60M | 14.56M | 1.44M | 0.00 | 23.40M |
Intelligent Bio Solutions Technical Analysis
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $5.89M | -3.60 | -223.45% | ― | 3.26% | 65.96% | |
41 Neutral | $10.30M | ― | ― | ― | ― | ― | |
41 Neutral | $3.62M | -0.05 | -296.20% | ― | -67.73% | 58.35% | |
38 Underperform | $5.58M | -0.06 | -245.18% | ― | -27.66% | 13.18% | |
26 Underperform | $9.13M | ― | ― | ― | ― | ― |
Intelligent Bio Solutions Corporate Events
On December 15, 2025, Intelligent Bio Solutions Inc. received a deficiency letter from Nasdaq due to its stock price falling below $1.00 for 30 consecutive business days, failing to meet the minimum bid price requirement for continued listing. The company has until June 15, 2026, to regain compliance, and has initiated a 1-for-10 reverse stock split to address this issue, effective December 15, 2025, with trading on a split-adjusted basis starting December 16, 2025.
On October 16, 2025, Intelligent Bio Solutions Inc. held its annual stockholder meeting where an amendment was approved to effect a reverse stock split. The company’s board decided on a 1-for-10 reverse stock split, which was filed on December 12, 2025, and became effective on December 15, 2025. This move reduced the number of outstanding shares from approximately 9.6 million to 960,000, with trading on a split-adjusted basis beginning on December 16, 2025. The reverse stock split aims to consolidate shares without altering the overall equity structure, except for cash payments in lieu of fractional shares.
Intelligent Bio Solutions Inc. provided a presentation to investors on December 2, 2025, detailing aspects of its business and operations. The presentation is available on the company’s website, and the information is furnished under Regulation FD, not filed under the Securities Exchange Act of 1934.
On November 25, 2025, Intelligent Bio Solutions Inc. issued 75,000 restricted shares of common stock to MDM Worldwide Solutions, Inc. as equity compensation for strategic communication advisory and consulting services. This issuance, exempt from registration under the Securities Act, reflects the company’s strategic move to enhance its communication capabilities without cash transactions.
On October 30, 2025, Intelligent Bio Solutions Inc. announced the addition of 33 new customer accounts during its fiscal first quarter ending September 30, 2025, marking a 50% increase from the previous year. This growth, particularly strong in the UK and supported by distributor activity in Europe and the Middle East, brings the total active accounts to over 480. The company’s expansion into sectors like government administration highlights the broadening applicability of its solutions. Approximately 91% of new accounts were first-time adopters of the company’s drug screening solution, indicating strong market penetration and customer confidence. The global drug screening market is projected to grow significantly, positioning Intelligent Bio Solutions to capitalize on this opportunity and drive sustainable revenue growth.
On October 16, 2025, Intelligent Bio Solutions Inc. held its annual meeting of stockholders, where an amendment to the 2019 Long Term Incentive Plan was approved, increasing the shares available for issuance by 495,000. The meeting also saw the election of directors, ratification of UHY LLP as the accounting firm, and approval of several proposals including a reverse stock split and issuance of shares upon warrant exercise.
On September 26, 2025, Intelligent Bio Solutions announced an update on their timeline for FDA 510(k) clearance of their Intelligent Fingerprinting Drug Screening System for codeine. Following feedback from the FDA, the company plans to initiate clinical studies by the end of 2025, aiming for clearance in the second half of 2026. This strategic move is expected to enhance their market positioning by expanding their product’s reach into the U.S. market, beyond its current forensic use, while maintaining growth in international markets.
On September 20, 2025, Intelligent Bio Solutions Inc. announced the extension of the termination date for its Series H-1 Common Stock Purchase Warrants from September 27, 2025, to March 27, 2026. This decision, which does not alter the exercise prices or other terms, was made with the consent of all six warrant holders, affecting 1,034,213 shares of common stock, and was executed without any additional consideration or agreements.